Featured Publications
Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictorsPrevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic
Elharake JA, Shafiq M, Cobanoglu A, Malik AA, Klotz M, Humphries JE, Murray T, Patel KM, Wilkinson D, Yildirim I, Diaz R, Rojas R, Cohen A, Lee A, Omer SB, Gilliam WS. Prevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic. Preventing Chronic Disease 2022, 19: e61. PMID: 36137183, PMCID: PMC9541678, DOI: 10.5888/pcd19.220132.Peer-Reviewed Original ResearchConceptsPhysical health conditionsMental healthHealth conditionsChronic diseasesDepression ratesCOVID-19 pandemicSex/gender disparityPublic health officialsChildcare professionalsSevere asthmaHeart diseaseUS adultsAsthma ratesSociodemographic characteristicsHealth officialsDepressionDiseaseNational representativenessLinear regression modelsPrevalenceHealthRegression modelsPandemicProfessionalsGender disparities
2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, 230: 1093-1101. PMID: 38536442, PMCID: PMC11565884, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults